VXA-G1.1-NN
Phase 1Completed 0 watching 0 views this week💤 Quiet
25
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Norovirus Infections
Conditions
Norovirus Infections
Trial Timeline
Jan 24, 2022 → Feb 24, 2022
NCT ID
NCT05213728About VXA-G1.1-NN
VXA-G1.1-NN is a phase 1 stage product being developed by Vaxart for Norovirus Infections. The current trial status is completed. This product is registered under clinical trial identifier NCT05213728. Target conditions include Norovirus Infections.
Hype Score Breakdown
Clinical
10
Activity
5
Company
2
Novelty
3
Community
2
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05213728 | Phase 1 | Completed |
| NCT04875676 | Phase 1/2 | Completed |
Competing Products
11 competing products in Norovirus Infections
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| VXA-G1.1-NN + VXA-G2.4-NS + Placebo Tablets | Vaxart | Phase 1 | 25 |
| VXA-G1.1-NN (high dose) Oral Vaccine Tablet + VXA-G1.1-NN (low dose) Oral Vaccine Tablet | Vaxart | Phase 1 | 25 |
| VXA-G1.1-NN + VXA-G2.4-NS + VXA G1.1 NN-T + VXA G2.4 NS-T | Vaxart | Phase 1 | 25 |
| VXA-G1.1-NN | Vaxart | Phase 1/2 | 33 |
| VXA-G1.1-NN Oral Vaccine | Vaxart | Phase 1 | 25 |
| Norwalk GI.1 Virus | Vaxart | Phase 1 | 25 |
| VXA-G1.1-NN + Norovirus GI.1 Norwalk Virus Inoculum | Vaxart | Phase 1/2 | 33 |
| Open label Bivalent GII.4/GI.1 high dose vaccine 2×10 to the power 11 IU/dose + Bivalent GII.4/GI.1 high dose vaccine 2×10 to the power 11 IU/dose + Bivalent GII.4/GI.1 medium dose vaccine 1×10 to the power 11 IU/dose + Placebo | Vaxart | Phase 2 | 44 |
| VXA-G1.1-NN + VXA-G2.4-NS + Placebo Tablets | Vaxart | Phase 1 | 25 |
| VXA-GI.1.NN + Placebo Tablet | Vaxart | Phase 1 | 25 |
| CDI-988 + Placebo | Cocrystal Pharma | Phase 1/2 | 33 |